NCT06210360View on ClinicalTrials.gov

Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

134

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

April 1, 2025

Study Completion Date

April 1, 2027

Conditions
Pancreatic Cancer
Interventions
DRUG

Irinotecan liposome injection

50 mg/m² on Day 1 of a 14 day cycle

DRUG

Oxaliplatin

60 mg/m² on Day 1 of a 14 day cycle

DRUG

5-FU

2400 mg/m² continuous IV infusion in 46 h

DRUG

LV

400 mg/m² on Day 1 of a 14 day cycle

All Listed Sponsors
lead

Changhai Hospital

OTHER